Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

200 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Autologous HSCT for advanced MS: is the glass half-empty or really half-full?
Nash RA, Stuve O, Bowen JD, Frohman EM, Griffith LM, Hutton GJ, Kraft GH, Popat U, Racke MK, Muraro PA. Nash RA, et al. Among authors: racke mk. Brain. 2008 Feb;131(Pt 2):e89; author reply e90. doi: 10.1093/brain/awm180. Epub 2007 Sep 30. Brain. 2008. PMID: 17908695 No abstract available.
High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report.
Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Griffith LM, Muraro PA, Openshaw H, Sayre PH, Stüve O, Arnold DL, Spychala ME, McConville KC, Harris KM, Phippard D, Georges GE, Wundes A, Kraft GH, Bowen JD. Nash RA, et al. Among authors: racke mk. JAMA Neurol. 2015 Feb;72(2):159-69. doi: 10.1001/jamaneurol.2014.3780. JAMA Neurol. 2015. PMID: 25546364 Free PMC article. Clinical Trial.
High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS.
Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Steinmiller KC, Griffith LM, Muraro PA, Openshaw H, Sayre PH, Stuve O, Arnold DL, Wener MH, Georges GE, Wundes A, Kraft GH, Bowen JD. Nash RA, et al. Among authors: racke mk. Neurology. 2017 Feb 28;88(9):842-852. doi: 10.1212/WNL.0000000000003660. Epub 2017 Feb 1. Neurology. 2017. PMID: 28148635 Free PMC article. Clinical Trial.
Hematopoietic stem cell transplantation for multiple sclerosis: collaboration of the CIBMTR and EBMT to facilitate international clinical studies.
Pasquini MC, Griffith LM, Arnold DL, Atkins HL, Bowen JD, Chen JT, Freedman MS, Kraft GH, Mancardi GL, Martin R, Muraro PA, Nash RA, Racke MK, Storek J, Saccardi R. Pasquini MC, et al. Among authors: racke mk. Biol Blood Marrow Transplant. 2010 Aug;16(8):1076-83. doi: 10.1016/j.bbmt.2010.03.012. Epub 2010 Mar 18. Biol Blood Marrow Transplant. 2010. PMID: 20304084 Free PMC article. Review.
Brain volume change after high-dose immunosuppression and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis.
Lee H, Nakamura K, Narayanan S, Brown RA, Nash RA, Griffith LM, Steinmiller KC, Devine SM, Hutton GJ, Popat U, Racke MK, Georges GE, Bowen JD, Arnold DL. Lee H, et al. Among authors: racke mk. Mult Scler Relat Disord. 2021 Sep;54:103149. doi: 10.1016/j.msard.2021.103149. Epub 2021 Jul 12. Mult Scler Relat Disord. 2021. PMID: 34284316
Multiple sclerosis--the plaque and its pathogenesis.
Frohman EM, Racke MK, Raine CS. Frohman EM, et al. Among authors: racke mk. N Engl J Med. 2006 Mar 2;354(9):942-55. doi: 10.1056/NEJMra052130. N Engl J Med. 2006. PMID: 16510748 Review. No abstract available.
Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy.
Stüve O, Cravens PD, Frohman EM, Phillips JT, Remington GM, von Geldern G, Cepok S, Singh MP, Tervaert JW, De Baets M, MacManus D, Miller DH, Radü EW, Cameron EM, Monson NL, Zhang S, Kim R, Hemmer B, Racke MK. Stüve O, et al. Among authors: racke mk. Neurology. 2009 Feb 3;72(5):396-401. doi: 10.1212/01.wnl.0000327341.89587.76. Epub 2008 Nov 5. Neurology. 2009. PMID: 18987352 Free PMC article. Clinical Trial.
200 results